Tactile Systems Technology

Tactile's direct‑to‑patient, clinician referral and in‑house reimbursement operations cause higher patient uptake and recurring rentals/sales, producing durable revenue growth independent of purely product innovation. If true, revenue growth will be resilient to competition and justify a premium multiple; if false, growth will be exposed to commoditization and payer cuts.

Manufacturing scale, better yields and product design improvements will reduce overhead as a percent of revenue and sustain high gross margins as unit volumes grow. Sustained high gross margins enable operating leverage—turning revenue growth into durable operating income and cash flow rather than margin erosion under payer pressure.

Commercial launches of Nimbl and the AffloVest line will increase patient penetration and expand the addressable market, providing a multi‑product growth engine beyond legacy Flexitouch units. If adoption of Nimbl/AffloVest meaningfully increases, revenue growth can accelerate and diversify payer exposure; failure leaves growth dependent on a single product family and vulnerable to payer pressure.

MD&A‑identified pricing pressure from private insurers will compress operating income unless Tactile either secures improved reimbursement coverage or achieves significant operating leverage. If pricing pressure materializes without offset, operating income and margins will fall despite stable unit demand, undermining valuation tied to current profitability.